StreetAlpha.app
Home › Stocks › DSGN

Design Therapeutics, Inc. (DSGN)

Healthcare
$9.84
▼ −0.81%
LAST CLOSE · NOV 17

Design Therapeutics develops GeneTAC small molecule drug candidates for inherited diseases caused by repeated gene sequences. It last closed at $9.84 on Nov 17, down 0.81% on the day. The average 12-month price target from 2 analysts is $22.50 (+128.7% from the last close), with a high of $26.00 and a low of $19.00.

AI Auto Pilots
Is DSGN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$74.1M
EPS (diluted)
−$1.20
Free cash flow
−$59.4M
Valuation
Market cap
$630.1M
64.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$15.3M
At Sep 30
Shareholder equity
$202.2M
Shares outstanding
64.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $0$0FY2025

From DSGN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated DSGN in the past 90 days, not enough for a consensus
Average 12-month target
$22.50
▲ 128.7% upside

Based on 2 analysts who set a price target on DSGN in the past 90 days. The average target is $22.50, with a high of $26.00 and a low of $19.00, compared with the last close of $9.84.

Low $19.00Avg $22.50High $26.00
Blue marker: last close $9.84
Highest target$26.00
Average target$22.50
Lowest target$19.00
Latest rating changes
RBC CapitalMaintained
Nov 5Buy$19
Wells FargoInitiated
Oct 2Buy$26
DateFirmActionRatingPrice target
Nov 5RBC CapitalMaintainedBuy$19
Oct 2Wells FargoInitiatedBuy$26
Loading…

Technical Analysis

DSGN · as of the Nov 17 close · updated after every close
Downtrend

The stock is 6% below its 20 day and 17% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the swing low (Nov 5) at $9.62, and the nearest resistance the Pivot at $9.87.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.5%/day
Key levels
$17.2552 week high+75.3%
$12.79100 day average+30.0%
$12.18200 day average+23.8%
$11.4850 day average+16.7%
$10.98Swing high (Nov 11)+11.6%
$10.4620 day average+6.3%
$10.20Pivot R1+3.7%
$9.87Pivot+0.3%
$9.84Last close
$9.62Swing low (Nov 5)−2.2%
$9.50Pivot S1−3.5%
$7.2452 week low−26.4%
Indicators
RSI (14)39.56Weak, oversold below 30Neutral
MACD-0.35Above its signal lineBullish
Stochastic26.4Middle of its rangeNeutral
ADX (14)16.6No clear trend
Williams %R-83.9Oversold below −80, overbought above −20Oversold
CCI (20)-159.2Oversold below −100, overbought above 100Oversold
Rate of change−4.8%Change over 10 sessionsBearish
ATR (14)$0.64Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DSGN

What happened before

See how DSGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow DSGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DSGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in DSGN in the last 90 days.

Loading…

See today’s whale options flow across the market →

DSGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲80 buying vs 50 selling
  • ▲Held by funds +3.6 pts
  • ▲Funds holding +4
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding142138+2.9%
In funds' top 1034−25.0%
Held by funds83.2%79.6%+3.6 pts
New / increased16 / 6428 / 61−10.1%
Reduced / sold out37 / 1332 / 16+4.2%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DSGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DSGN is in one of them and how their past DSGN trades turned out.

DSGN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DSGN in an article yet. Here's the latest on the wider market.

About Design Therapeutics

Design Therapeutics is a biopharmaceutical company based in Carlsbad, California, that researches and develops GeneTAC molecules, a type of small molecule. These molecules are designed to target repeated DNA sequences that cause certain inherited diseases, and to adjust how genes are expressed in affected cells. The company's lead candidates are aimed at Friedreich ataxia, Fuchs endothelial corneal dystrophy and myotonic dystrophy type 1. Its candidates are still in development and are intended for patients with these inherited conditions.

Headquarters
Carlsbad, CA